Photo via Pexels
Researchers at the University of California, Berkeley, led by Professor Jennifer Doudna and Dr. Stanley Qi, developed a CRISPR-based antiviral strategy called PAC-MAN (Prophylactic Antiviral Crispr in human cells) that can degrade the RNA of coronaviruses and influenza viruses. The system utilizes Cas13 enzymes guided by specific RNA sequences to target and cleave viral RNA, effectively neutralizing the pathogen. In laboratory tests, PAC-MAN was shown to reduce SARS-CoV-2 viral RNA in human lung cells by over 90%, and also demonstrated efficacy against influenza A virus. This novel approach represents a broad-spectrum antiviral that could potentially be delivered into the lungs to prevent or treat respiratory viral infections. The promising results were published in *Nature Biomedical Engineering* in August 2020.
Editorial check
How this page is checked
Source trail
cell.com
External links are separated from Surfaced commentary.
Reader safety
Context before clicks
Product links and external services are not presented as guarantees.
Monetization
No affiliate flag
Ads and commerce links are kept distinct from editorial text.
Surfaced take
Why It’s Fascinating
This discovery is groundbreaking because it offers a precise, programmable antiviral strategy that could target a wide array of RNA viruses, overcoming the limitations of traditional vaccines and small-molecule drugs that often target specific viral proteins. It confirms the versatility of CRISPR technology beyond gene editing, extending its application to directly combating viral threats. Within 5-10 years, PAC-MAN or similar CRISPR-based antivirals could be developed into inhaled therapies, like nebulized treatments, offering a rapid response to emerging viral pandemics or even seasonal flu outbreaks. Imagine a microscopic 'search and destroy' drone that can be programmed to find and dismantle the genetic instructions of any invading virus in your cells. Patients suffering from severe respiratory viral infections and public health officials facing new pandemics stand to benefit most. Could such a system be adapted to provide preventative, 'on-demand' antiviral protection for individuals at high risk? This approach contrasts with typical small-molecule antivirals, which often inhibit viral replication but don't directly destroy the viral genome itself.
Related
A couple million lines of Haskell: Production engineering at Mercury
This article, 'A couple million lines of Haskell: Production engineering at Mercury,' details the sophisticated engineering practices at Mercury, a financial…
Streaky - Simple Habit Tracker
Streaky, developed by Michael Furtak, is a straightforward and aesthetically clean habit tracker available for iOS, designed for users who prefer simplicity…
Enjoyed this? Get five picks like this every morning.
Free daily newsletter — zero spam, unsubscribe anytime.